Category Archives: SMFM

House, Senate Agree on Key SMFM-backed Language Assessing Research in Pregnancy and Breastfeeding

WASHINGTON, Nov. 28, 2016– In 2014, the Society for Maternal-Fetal Medicine began working with the March of Dimes, the American Congress of Obstetricians and Gynecologists, and the American Academy of Pediatrics to form the Coalition to Advance Maternal Therapeutics. The Coalition has been working to educate and inform Congress and other policymakers on the issues related to lack of data and information on medications in pregnancy and breastfeeding, recently hosting a congressional briefing on the topic.

In February 2015, SMFM hosted a workshop on the issue of medications in pregnancy and breastfeeding at its annual meeting, which was co-sponsored by the National Institute of Child Health and Human Development, American Academy of Pediatrics, and American Congress of Obstetricians and Gynecologists. The workshop explored the issue of medications used during pregnancy and breastfeeding, with participants agreeing that more research was necessary to ensure that safe and effective drugs are being prescribed to women who need them during pregnancy and lactation.

SMFM, with the CAMT, advocated for the creation of a task force housed within the U.S. Department of Health and Human Services that will improve federal interagency and key stakeholder communication, coordination and collaboration to advance research and information sharing on medications in pregnancy and breastfeeding.  This Task Force has been included in the bipartisan, negotiated 21st Century Cures Act. The task force will include federal agencies such as National Institutes of Health, U.S. Food & Drug Administration, and Centers for Disease Control and Prevention as well as public stakeholders from professional societies, consumer representation and industry representation to prioritize and identify gaps in research and recommend a path forward on greater inclusion of pregnant and breastfeeding women in medication research.

Dr. Mary Norton, president of SMFM, released the following statement:

“We applaud Congress for making the right decision in creating a Task Force on Research in Pregnant Women and Lactating Women in the final 21st Century Cures Act, slated for a vote in the House this week, and hope for swift action by the Senate shortly following. SMFM has been dedicated to moving this important initiative for several years, founding the Coalition to Advance Maternal Therapeutics – whose steering committee includes the American Academy of Pediatrics, American Congress of Obstetricians & Gynecologists and March of Dimes, as well as SMFM.

“SMFM would like to especially acknowledge Senator Patty Murray and Representatives Jaime Herrera Beutler and Kathy Castor for continuing to lead the efforts to ensure that this language made it into the final legislative package, which has strong bipartisan support.

“More women with chronic diseases are becoming pregnant, yet safe and effective medications to manage these ongoing conditions throughout their pregnancy and beyond are needed. This legislation is a great first step toward greater collaboration and communication among federal agencies and public stakeholders.

“We look forward to ensuring that the work of this task force will inform our members and patients and strongly support this legislation’s passage and seeing President Obama sign it into law.”

# # #

Nation’s Health Experts Look to Improve Maternal Care

Nation’s Health Experts Look to Improve Maternal Care

ACOG and SMFM issue new guidance on Severe Maternal Morbidity:

Screening and Review

 WASHINGTON, Aug. 23, 2016 Each year, more than 65,000 women in the United States suffer complications during pregnancy or childbirth that are near-fatal. In many cases, these outcomes may have been prevented. Like maternal mortality, defined as the death of a woman during pregnancy, at delivery or soon after delivery, maternal morbidity in the United States has been steadily increasing. A maternal morbidity is an unintended outcome in the process of labor and delivery that results in significant short-term or long-term consequences to a woman’s health.

Today, as part of a continued effort to reduce maternal morbidity and mortality across the country, organizations representing women’s health care providers released new guidance on the screening and review of maternal morbidity. Severe Maternal Morbidity: Screening and Review is the fifth in the joint American College of Obstetricians and Gynecologists (ACOG) and Society for Maternal-Fetal Medicine (SMFM) Obstetric Care Consensus Series.

Maternal morbidity can be considered a “near miss” for maternal mortality because, in some cases, without identification and treatment the conditions that define maternal morbidity would lead to maternal death. Therefore, the importance of identifying a potential maternal morbidity is paramount. Identification can also highlight opportunities to avoid such injuries in other women in the future.

“Obstetrician-gynecologists always want the best, healthiest outcomes for both mother and child. That is why our Obstetric Care Consensus Series aims to improve maternal safety across the country,” said Sarah J. Kilpatrick, M.D./Ph.D., chair of the Department of Obstetrics and Gynecology at Cedars-Sinai Medical Center in Los Angeles, California, and a lead author of the document. “Developing systems that help us identify severe maternal morbidity will ultimately help provide better care. The two-step approach discussed in the document involves a screen to identify potential cases of severe maternal morbidity, followed by a review to help better understand the event, including determining if the morbidity was potentially avoidable.”

Multidisciplinary expert groups have called for all obstetric hospitals to review their cases of severe maternal morbidity in order to recognize opportunities for improvement in care. Building off this recommendation, ACOG and SMFM recommend using a two-step screen and review process to identify severe maternal morbidity.

First, they recommend facilities have a screening process in place to detect potential cases. ACOG and SMFM recommend using the following two criteria as a screen, although institutions may choose to incorporate additional criteria:

  • Transfusion of four or more units of blood
  • Admission of a pregnant or postpartum woman to an ICU

Second, facilities should then review all cases that meet at least one of these screening criteria to efficiently detect severe maternal morbidity and determine whether there were opportunities for improvement in care. Institutions may also elect to define additional screening criteria if deemed useful in their setting.

ACOG and SMFM are careful to highlight that not all cases of severe maternal morbidity are preventable. Some cases of morbidity reflect the underlying health of a woman or her pregnancy and are thus unavoidable. Therefore, simply screening positive for one of the two recommended screening criteria does not constitute a sentinel event and rates of occurrence of either criterion should not be used as a quality metric.

While the document provides an example list of conditions that could constitute severe maternal morbidity, there is no consensus on a comprehensive list of conditions. This underscores the importance of institutions and systems either adopting an existing screening criteria or creating their own list of outcomes that merit review.

“The intent of this document is to provide a standard, evidence-based approach to help obstetric providers and their facilities more easily recognize cases of severe maternal morbidity which deserve more detailed review, “Dr. Kilpatrick continued. “These criteria and the examples listed in the document are not categorical definitions and should not be misconstrued as quality measures. Rather, we understand that as women’s health care physicians we need to be at the forefront of developing a reference to identify severe maternal morbidity and that’s what this document is intended to do.”

“Quality improvement is something all obstetrician-gynecologists should be actively involved in—regardless of hospital size, location, or low- or high-risk pregnancy status. There is almost always something to learn about our systems following these types of complex cases. We owe it to our future patients to continuously improve the care we provide and this document will help these efforts,” stated Dr. Sean Blackwell, chair of the publications committee for the SMFM and chair of the Department of Obstetrics, Gynecology and Reproductive Sciences at McGovern Medical School at The University of Texas Health Science Center at Houston.

In addition to this newly-released guidance, ACOG and SMFM have been long-standing lead partners in the Alliance for Innovation on Maternal Health (AIM), a national alliance to promote consistent and safe maternity care to reduce maternal mortality and severe maternal morbidity.

Other recommendations issued in the September Obstetrics & Gynecology:

Committee Opinion #671, Perinatal Risks Associated With Assisted Reproductive Technology

Over the past decades, the use of assisted reproductive technology (ART) has increased dramatically worldwide and has made pregnancy possible for many infertile couples. Although the perinatal risks that may be associated with ART and ovulation induction are much higher in multifetal gestations, even singletons achieved with ART and ovulation induction may be at higher risk than singletons from naturally occurring pregnancies. However, it remains unclear to what extent these associations might be related to the underlying cause(s) of infertility. Before initiating ART or ovulation induction procedures, obstetrician–gynecologists and other health

care providers should complete a thorough medical evaluation to ensure that patients are in good health and should counsel these women about the risks associated with treatment. Any maternal health problems or inherited conditions should be addressed. Couples at risk of passing genetic conditions on to their offspring, including those due to infertility-associated conditions, should be counseled appropriately. When a higher-order (triplet or more) multifetal pregnancy is encountered, the option of multifetal reduction should be discussed. In the case of

a continuing higher-order multifetal pregnancy, ongoing obstetric care should be with an obstetrician–gynecologist or other obstetric care provider and at a facility capable of managing anticipated risks and outcomes.

Committee Opinion #672, Clinical Challenges of Long-Acting Reversible Contraceptive Methods

Long-acting reversible contraceptive methods are the most effective reversible contraceptives and have an excellent safety record. Although uncommon, possible long-acting reversible contraceptive complications should be included in the informed consent process. Obstetrician–gynecologists and other gynecologic care providers should understand the diagnosis and management of common clinical challenges. The American College of Obstetricians and Gynecologists recommends the algorithms included in this document for management of the most common clinical challenges.

Committee Opinion #673, Persistent Vulvar Pain

Persistent vulvar pain is a complex disorder that frequently is frustrating to the patient and the clinician. It can be difficult to treat and rapid resolution is unusual, even with appropriate therapy. Vulvar pain can be caused by a specific disorder or it can be idiopathic. Idiopathic vulvar pain is classified as vulvodynia. Although optimal treatment remains unclear, consider an individualized, multidisciplinary approach to address all physical and emotional aspects possibly attributable to vulvodynia. Specialists who may need to be involved include sexual counselors, clinical psychologists, physical therapists, and pain specialists. Patients may perceive this approach to mean the practitioner does not believe their pain is “real”; thus, it is important to begin any treatment approach with a detailed discussion, including an explanation of the diagnosis and determination of realistic treatment goals. Future research should aim at evaluating a multimodal approach in the treatment of vulvodynia, along with more research on the etiologies of vulvodynia.

Committee Opinion #674, Guiding Principles for Privileging of Innovative Procedures in Gynecologic Surgery

New or emerging surgical procedures and technologies continue to be developed at a rapid rate and must be implemented safely into clinical practice. Additional privileging may be required if substantively new technical or cognitive skills are required to implement an innovative procedure or technology. Guiding principles for privileging should include cognitive and technical assessment to ensure appropriate patient selection and performance of the new procedure. Implementation also should include pertinent institutional and staff support as needed. A dynamic process for assessment and maintenance of current competency will enhance the safety of implementation and continued application of emerging procedures and technologies. The number of cases needed to demonstrate cognitive and technical proficiency will vary depending on many factors, including the health care provider’s baseline expertise and technical acumen.

Practice Bulletin #166, Thrombocytopenia in Pregnancy

Thrombocytopenia in pregnant women is diagnosed frequently by obstetricians because platelet counts are included with automated complete blood cell counts (CBCs) obtained during routine prenatal screening (1). Although most U.S. health care providers are trained using U.S. Conventional Units, most scientists, journals, and countries use Système International (SI) units. The laboratory results reported in U.S. Conventional Units can be converted to SI Units or vice versa by using a conversion factor. The conversion factor for platelet count results is 1.0 (ie, to convert from x 103/μL, multiply by 1.0, to get x 109/L). Thrombocytopenia, defined as a platelet count of less than 150 x 109/L, is common and occurs in 7–12% of pregnancies (2, 3). Thrombocytopenia can result from a variety of physiologic or pathologic conditions, several of which are unique to pregnancy. Some causes of thrombocytopenia are serious medical disorders that have the potential for maternal and fetal morbidity. In contrast, other conditions, such as gestational thrombocytopenia, are benign and pose no maternal or fetal risks. Because of the increased recognition of maternal and fetal thrombocytopenia, there are numerous controversies about obstetric management of this condition. Clinicians must weigh the risks of maternal and fetal bleeding complications against the costs and morbidity of diagnostic tests and invasive interventions.

###

Key Committee Votes to Create Task Force on Pregnant and Lactating Women to Ensure Safer Medications, Collaboration on Research and Wider Dissemination of Information

WASHINGTON, April 18, 2016—The Society for Maternal-Fetal Medicine announced today that the Senate Health Education Labor & Pensions (HELP) Committee has approved bill S. 2745 by voice vote, a bill intended to promote the inclusion of minorities in clinical research. This legislation includes a key provision that would create a Task Force on Pregnant Women and Lactating Women.

SMFM held a workshop on the issue of medications in pregnancy and breastfeeding at its annual meeting in February 2015, which was co-sponsored by the National Institute of Child Health and Human Development, American Academy of Pediatrics and American Congress of Obstetricians and Gynecologists.

“We are thrilled to see this initiative move to the next step in the legislative process,” stated Mary Norton, M.D., president of SMFM. “As more women with chronic diseases, such as diabetes, hypertension, depression and asthma are becoming pregnant, safe and effective medications to manage these ongoing conditions throughout their pregnancy and beyond are needed. This legislation is a great first step toward greater collaboration and communication among federal agencies and public stakeholders on this important issue.”

In her opening statement, HELP Committee Ranking Member Senator Patty Murray (D-WA), noted her thanks to the legislation’s cosponsors, including Senators Susan Collins (R-ME), Kirk (R-IL), Baldwin (D-WI), Warren (D-MA) and Chairman Alexander (R-TN) and herself. She noted specifically the inclusion of this task force to ensure safer medications and greater information for pregnant women and new mothers.

In 2014, SMFM began working with the March of Dimes, the American Congress of Obstetricians and Gynecologists, and the American Academy of Pediatrics to form the Coalition to Advance Maternal Therapeutics. The Coalition has been working to educate and inform Congress and other policymakers on the issues related to lack of data and information on medications in pregnancy and breastfeeding.

The provision included in S. 2745 will created a task force housed within the U.S. Department of Health and Human Services that will improve federal interagency and key stakeholder communication, coordination and collaboration to advance research and information sharing on medications in pregnancy and breastfeeding.  It will include federal agencies such as National Institutes of Health, U.S. Food & Drug Administration and Centers for Disease Control and Prevention as well as public stakeholders from professional societies, consumer representation and industry representation to prioritize and identify gaps in research and recommend a path forward on greater inclusion of pregnant and breastfeeding women in research.

# # #

SMFM Releases Statement on Ultrasound Screening for Fetal Microcephaly following Zika Virus Exposure

WASHINGTON (April 13, 2016)— The Society for Maternal-Fetal Medicine released a statement on the use of ultrasound screening for fetal microcephaly following Zika virus exposure.

Microcephaly is a condition in which the size of the head is smaller than expected for age. This condition in fetuses and infants has been associated with the recent outbreak of Zika virus.  Due to this association, the Centers for Disease Control and Prevention, American Congress of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine have suggested ultrasound evaluation to measure the baby’s head in pregnant women who have been infected or potentially exposed.  Diagnosis of microcephaly by ultrasound is not always straightforward and can be complex. The Society for Maternal-Fetal Medicine provided recommendations on how to interpret the findings, including when to perform follow up ultrasound, as well as a table of values at each week of pregnancy that would define the lower limit of normal. The goal is to provide the tools to health care providers to counsel women who may have been exposed to the Zika virus. The Society for Maternal-Fetal will continue to assist clinicians in tackling this new health threat.

For more information on the Society of Maternal-Fetal Medicine’s recommendations and the Zika virus, go to www.smfm.org/education/zika or visit SMFM’s publications www.smfm.org/publications.

# # #

Society for Maternal-Fetal Medicine Releases Statement on use of Antenatal Corticosteroids in the Late Preterm Birth Period in Women at Risk for Preterm Birth

WASHINGTON (April 6, 2016)— The Society for Maternal-Fetal Medicine released a statement on the use of antenatal corticosteroids during the late preterm birth period for women at risk of preterm birth. The statement, is currently available online and will be published in the July issue of the American Journal of Obstetrics and Gynecology. It comes on the heels of a study and a presentation at SMFM’s annual meeting in Atlanta in February where researchers with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and Maternal-Fetal Medicine Units Network (MFMU) presented findings that the administration of antenatal steroids in pregnancies at risk for late preterm delivery prevents respiratory and other neonatal complications.

The study, titled Antenatal Late Preterm Steroids (ALPS): a Randomized Trial to Reduce Neonatal Respiratory Morbidity was a randomized, double-blind, placebo-controlled trial at 17 tertiary medical centers around the United States from Oct. 2010 to Feb. 2015.  The study enrolled 2,831 women with singleton pregnancies at high risk for late preterm delivery (34 0/7 to 36 6/7 weeks) who were randomized to receive antenatal betamethasone intramuscularly or a matching placebo.  This study found a significant decrease in neonatal respiratory complications in the group given the steroid treatment.  Investigators also found that these babies were less likely to have prolonged intensive care nursery stays, less likely to need postnatal treatment for respiratory complications, and less likely to develop bronchopulmonary dysplasia, which is a sign of chronic lung disease. Prior to this report, such treatment was only recommended with risk of preterm delivery before 34 weeks of gestation, as infants in the late preterm period were thought to be at little, if any, increased risk of complications.

Lead investigator, Cynthia Gyamfi-Bannerman, M.D., MSc, the Ellen Jacobson Levine and Eugene Jacobson Associate Professor of Women’s Health (in Obstetrics and Gynecology) from Columbia University Medical Center, put the findings in context: “The majority of preterm deliveries occur in the late preterm period.  We now have a treatment that can significantly improve outcomes for these at risk babies.”  The study was co-funded by the NHLBI, with the aid of program officer Carol Blaisdell, M.D. and the NICHD under the guidance of Uma Reddy, M.D.

In their statement, the Society for Maternal-Fetal Medicine recommends:

  • In women with a singleton pregnancy between 34 weeks to 36 6/7 weeks of gestation who are at high risk for preterm birth within the next seven days (but before 37 weeks of gestation), SMFM recommends treatment with betamethasone, a corticosteroid demonstrated to decrease neonatal complications in preterm infants.
  • In women with preterm labor symptoms in the late preterm period, SMFM recommends waiting for evidence of true preterm labor, such as a cervical dilatation of at least three centimeters or effacement of at least 75% before treatment with betamethasone.
  • In women with late preterm pregnancies receiving betamethasone, SMFM recommends against the use of tocolysis in an attempt to delay delivery to complete the steroid course since it is unclear if the benefits are outweighed by the risks of attempts to delay delivery.
  • In women with late preterm pregnancies with a potential medical indication for delivery, SMFM recommends betamethasone not be given unless there is a definitive plan for late preterm delivery.
  • SMFM also recommends against the implementation of antenatal late preterm steroids protocol for conditions not studied in the randomized controlled trials.

Given that more than 300,000 pregnancies deliver in the late preterm period each year in the U.S., the study along with recommendations for adoption by the Society for Maternal-Fetal Medicine will have a significant impact on the health of newborns and infants.

For more information on SMFM publications, go to https://www.smfm.org/publications.

Study Finds Maternal Intake of High Fructose Leads to Fetal Programming of Adult Obesity, Hypertension and Metabolic Dysfunction Especially in Female Offspring

ATLANTA (Feb. 4, 2016)—In a study to be presented on Feb. 5 in the oral session at 1:15 p.m. EST, at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting™, in Atlanta, researchers will present findings on the effects of antenatal exposure to a high fructose diet on the offspring’s development of metabolic syndrome-like phenotype and cardiovascular disease later in life.

The study, titled High fructose diet in pregnancy leads to fetal programming of hypertension, insulin resistance and obesity in adult offspring, randomly allocated either a fructose solution or water as the only drinking fluid for pregnant mice from first day of pregnancy through delivery. Offspring were then started on regular chow and evaluated after one year of life.  Percent of visceral adipose tissue was measured along with liver fat infiltrates using computed tomography, and blood pressure using a non-invasive monitor. Glucose tolerance testing was also performed and serum concentrations of glucose, insulin, triglycerides, total cholesterol, leptin and adiponectin were measured.

Maternal weight, pup number and average weight at birth were similar between the two groups. Male and female offspring born to mothers who received the fructose solution group had higher peak glucose compared with controls. Female offspring from the fructose group were heavier and had a higher percent of visceral adipose tissue, liver fat infiltrates, fasting homeostatic model assessment scores, higher serum concentrations of leptin and lower concentrations of adiponectin.

No significant differences in these parameters were noted in male offspring. Serum concentrations of triglycerides and total cholesterol were not different between the two groups or either gender.

“While this study was done in a mouse model, it is an important indicator of the effect of the mothers’ diet during pregnancy on the health of their children later in life,” explained Antonio Saad, M.D. with UTMB Galveston and the lead researcher of the study. “Through this study, we know that consuming high fructose during pregnancy putts the child at future risk for a variety of health conditions including obesity and the many complications it causes.”

The study concluded that, while maternal intake of high fructose leads to fetal programming of adult obesity, hypertension, and metabolic dysfunction—all of which risk factors for cardiovascular disease; limiting high fructose enriched diets in pregnancy may have a significant impact on long term health.

 

# # #

A copy of the abstract is available at http://www.smfmnewsroom.org and below. For interviews please contact Vicki Bendure at Vicki@bendurepr.com 202-374-9259 (cell).

 

The Society for Maternal-Fetal Medicine (est. 1977) is the premiere membership organization for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. The society is devoted to reducing high-risk pregnancy complications by sharing expertise through continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual meeting in which groundbreaking new ideas and research in the area of maternal-fetal medicine are shared and discussed.  For more information visit www.smfm.org.

 

Abstract 67    High Fructose Diet in Pregnancy Leads to Fetal Programming of Hypertension, Insulin Resistance and Obesity in Adult Offspring

 

Authors: Antonio Saad1, Joshua Disckerson1, Phyllis Gamble1, Huaizhi Yin1, Talar Kechichian1, Ashley Salazar1, Igor Patrikeev2, Massoud Motamedi2, George Saade1, Maged Costantine1

1UTMB Galveston, Galveston, TX, 2UTMB Center of Biomedical Engineering, Galveston, TX

 

Objective: Consumption of fructose rich diets in the U.S is on the rise and thought to be associated with obesity and cardio-metabolic diseases. Our objective was to determine the effects of antenatal exposure to high fructose diet on offspring’s development of metabolic syndrome-like phenotype and other cardiovascular disease (CVD) risk factors later in life.
Study Design: Pregnant C57BL/6J dams were randomly allocated to fructose solution (FRC, 10% W/V, n=10) as only drinking fluid or water (CTR, n=10) from day 1 of pregnancy until delivery. Pups were then started on regular chow, and evaluated at 1 year of life. We measured % visceral adipose tissue (VAT) and liver fat infiltrates using computed tomography (CT), and blood pressure using CODA/ non-invasive monitor. Intraperitoneal glucose tolerance testing (IPGTT), with corresponding insulin concentrations were obtained. Serum concentrations of glucose, insulin, triglycerides (TG), total cholesterol (TC), leptin, and adiponectin were measured in duplicate using standardized assays. Fasting homeostatic model assessment (HOMA- IR) was also calculated to assess insulin resistance.
Results: Maternal weight, pup number and average weight at birth were similar between the two groups. Male and female FRC offspring had higher peak glucose and area under the IPGTT curve, compared with CTR (Figures 1A&B), and higher mean arterial pressure compared to CTR (Figure 1C). Female FRC offspring were heavier and had higher % VAT (Figure 1D), liver fat infiltrates, HOMA-IR scores, insulin area under the IPGTT curve, serum concentrations of leptin, and lower concentrations of adiponectin compared to female CTR offspring (Table). No significant differences in these parameters were noted in male offspring. Serum concentrations of TG or TC were not different between the 2 groups for either gender.
Conclusion: Maternal intake of high fructose leads to fetal programming of adult obesity, hypertension and metabolic dysfunction, all risk factors for CVD. This fetal programming is more pronounced in female offspring. Limiting intake of high fructose enriched diets in pregnancy may have significant impact on long term health.

 

Abstract 67a

Abstract 67b

Study Shows Maternal Diet Alters the Breast Milk Microbiome and Microbial Gene Content

ATLANTA (Feb. 1, 2016)—In a study to be presented on Feb. 5 at 2:30 p.m. EST, at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting™, in Atlanta, researchers will present findings from a study titled, Maternal Diet Alters the Breast Milk Microbiome and Microbial Gene Content.

Breast milk contains a diverse microbiome that is presumed to colonize the infant gastrointestinal tract and contribute to the establishment of the infant gut microbiome. The composition of the breast milk microbiome varies over time and among individuals, though the factors driving the variation are largely unknown. Since maternal diet during gestation and lactation has been previously shown to independently alter the offspring microbiome and offspring disease susceptibility, researchers speculated that the breast milk microbiome may be a mediator of this dietary impact. Two groups of lactating women participated in highly-controlled single-blinded cross-over dietary intervention studies to evaluate if maternal diet plays a significant role in structuring the taxonomic and metagenomic composition of the breast milk microbiome.

“We saw considerable differences based on maternal diet,” explained Kristen Meyer, with the Baylor College of Medicine, one of the researchers of the study and the presenter at the SMFM annual meeting. “Based on this, we speculate that the maternal diet serves as a significant driver of the early infant microbiome, reinforcing the gestational dietary impact,” added Meyer.

# # #

A copy of the abstract is available at http://www.smfmnewsroom.org and below. For interviews please contact Vicki Bendure at Vicki@bendurepr.com 202-374-9259 (cell).

 

The Society for Maternal-Fetal Medicine (est. 1977) is the premiere membership organization for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine. The society is devoted to reducing high-risk pregnancy complications by sharing expertise through continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual meeting in which groundbreaking new ideas and research in the area of maternal-fetal medicine are shared and discussed.  For more information visit www.smfm.org.

 

abstract 66

The Benefits of Chocolate During Pregnancy

ATLANTA (Feb. 1, 2016)—In a study to be presented on Feb. 4 at 1:15 p.m. EST, at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting™, in Atlanta, researchers will present findings from a study titled, High-flavanol chocolate to improve placental function and to decrease the risk of preeclampsia: a double blind randomized clinical trial.

In light of previous studies showing conflicting results regarding the role of chocolate consumption during pregnancy and the risk of preeclampsia, this study set out to evaluate the impact of high-flavanol chocolate.  Researchers conducted a single-center randomized controlled trial of 129 women with singleton pregnancy between 11 and 14 weeks gestation who had double-notching on uterine artery Doppler.  The pregnant women selected were randomized to either high-flavanol or low-flavanol chocolate. A total of 30 grams of chocolate was consumed daily for 12 weeks and women were followed until delivery.  Uterine artery Doppler pulsatility index was at baseline and 12 weeks after randomization. Preeclampsia, gestational hypertension, placenta weight, and birthweight were also evaluated.

The result was that there was no difference in preeclampsia, gestational hypertension, placental weight or birthweight in the two groups; however, the uterine artery Doppler pulsatility index (a surrogate marker of blood velocity in the uterine, placental and fetal circulations) in both groups showed marked improvement that was much greater than expected in general population.

“This study indicates that chocolate could have a positive impact on placenta and fetal growth and development and that chocolate’s effects are not solely and directly due to flavanol content,” explained Emmanuel Bujold, M.D., one of the researchers on the study who will present the findings.  Dr. Bujold and Dr. Sylvie Dodin, principal investigator of the trial, are with the Université Laval Québec City, Canada.

# # #

A copy of the abstract is available at http://www.smfmnewsroom.org and below.  For interviews please contact Vicki Bendure at Vicki@bendurepr.com 202-374-9259 (cell).

The Society for Maternal-Fetal Medicine (est. 1977) is the premiere membership organization for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine.  The society is devoted to reducing high-risk pregnancy complications by sharing expertise through continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual meeting in which groundbreaking new ideas and research in the area of maternal-fetal medicine are shared and discussed.  For more information visit www.smfm.org.

Abstract 32    High-flavanol chocolate to improve placental function and to decrease the risk of preeclampsia: a double blind randomized clinical trial

Authors: Emmanuel Bujold1, Asma Babar1, Elise Lavoie1, Mario Girard2, Vicky Leblanc1, Simone Lemieux1, Lionel-Ange Poungui1, Isabelle Marc1, Belkacem Abdous1, Sylvie Dodin1

1Université Laval, Québec City, QC, Canada, 2Centre de recherche du CHU de Québec, Québec City, QC, Canada

Objective: Previous studies showed conflicting results regarding the role of chocolate consumption during pregnancy and the risk of preeclampsia. We aimed to evaluate the impact of high-flavanol chocolate in a randomized clinical trial.

Study Design: We conducted a single-center randomized controlled trial including women with singleton pregnancy between 11 and 14 weeks gestation who had double-notching on uterine artery Doppler. The pregnant women selected were randomized to either high-flavanol (HFC) or low-flavanol chocolate (LFC). A total of 30 g of chocolate was consumed daily for 12 weeks and women were followed until delivery. Uterine artery Doppler pulsatility index (UtA PI), reported as multiple of medians (MoM) adjusted for gestational age, was assessed at baseline and 12 weeks after randomization. Preeclampsia, gestational hypertension, placenta weight, and birthweight were also evaluated.

Results: One hundred twenty nine women were randomized at a mean gestational age of 12.4 ± 0.6 weeks with a mean UtA PI of 1.4 ± 0.4 MoM. Although adjusted UtA PI significantly decreased from baseline to 12 weeks in the 2 groups (<0.0001), the difference between the 2 groups was not significant (p=0.16). At 12 weeks, we observed no significant difference between HFC and LFC groups in the rate of preeclampsia (4.7% vs 3.1%, p=0.49) and gestational hypertension (6.2% vs 12.5%, p=0.56). Placental weight (466 vs 464 grams), p=0.93) and birthweight (3348 vs 3215 grams, p=0.07) were comparable between the two groups.

Conclusion: Compared with low-flavanol chocolate, daily intake of 30g of high-flavanol chocolate did not improve placental function, placental weight and the risk of preeclampsia. Nevertheless, the marked improvement of the pulsatility index observed in the 2 chocolate groups might suggest that chocolate effects are not solely and directly due to flavanol content.

Study Shows Impact of Sleep on Gestational Weight Gain During Pregnancy

ATLANTA (Feb. 1, 2016)—In a study to be presented on Feb. 4 at 1:15 p.m. EST, at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting™, in Atlanta, researchers will present findings from a study titled, Short and long sleep durations in pregnancy are associated with extremes of gestational weight gain.

Epidemiologic data from non-pregnant women has linked poor sleep with obesity and weight gain. The researchers in this study set out to determine the relationship between objectively measured sleep duration and weight gain during pregnancy.

Women studied were enrolled in the nuMoM2b study, a multi-center prospective cohort study of nulliparous women with a singleton gestation. They were recruited to wear an actigraph to record objective sleep activity for seven consecutive days. Women with pregestational diabetes and chronic hypertension were excluded from the study. Sleep duration was calculated as an average across study nights.  Actigraphy and weight gain data were reviewed for 751 women.  The majority of women (74.8%) had a sleep duration between seven and nine hours.

The data suggested that both short and long sleep duration in pregnancy are associated with gestational weight gain.  “We know that poor sleep in pregnancy has been linked to adverse pregnancy outcomes,” explained Francesca Facco, M.D., one of the researchers of the study who is with the Eunice Kennedy Shriver NICHD NuMoM2b Network in Bethesda, Md.  Dr. Facco will present the findings at the SMFM annual meeting. “Our findings provide a potential mechanism for poor sleep in pregnancy and adverse outcomes,” Facco added.

# # #

A copy of the abstract is available at http://www.smfmnewsroom.org and below.  For interviews please contact Vicki Bendure at Vicki@bendurepr.com 202-374-9259 (cell).

The Society for Maternal-Fetal Medicine (est. 1977) is the premiere membership organization for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine.  The society is devoted to reducing high-risk pregnancy complications by sharing expertise through continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual meeting in which groundbreaking new ideas and research in the area of maternal-fetal medicine are shared and discussed.  For more information visit www.smfm.org.

Abstract 33    Short and long sleep durations in pregnancy are associated with extremes of gestational weight gain

Authors: Francesca Facco1,2, Kathryn Reid3,1, William Grobman3,1, Corette Parker4,1, Shannon Hunter4,1, Matthew Koch4,1, Phyllis Zee3,1

1for the Eunice Kennedy Shriver NICHD NuMoM2b Network, Bethesda, MD, 2Magee-Womens Research Institute, University of Pittsburgh, Pittsburgh, PA, 3Northwestern University, Chicago, IL, 4RTI International, Triangle Park, NC

Objective: Epidemiologic data from non-pregnant cohorts have linked poor sleep with obesity and weight gain. Our objective was to determine the relationship between objectively measured sleep duration and weight gain in pregnancy.

Study Design: Women enrolled in the nuMoM2b study, a multi-center prospective cohort study of nulliparous women with a singleton gestation, were recruited at the 2nd study visit (16- 21 weeks’) to wear an actigraph to record objective sleep activity for 7 consecutive days. Women with pregestational diabetes and chronic hypertension were excluded. Sleep duration (SD) was calculated as an average across study nights and categorized as follows: <6, 6 to <7, 7 to <8, 8 to <9, and >9 hours/night. Gestational weight gain (GWG) was calculated relative to self-reported prepregnancy weight using measured weights at visit 2 and visit 3 (22-29 weeks’), and chart abstracted last weight prior to delivery. We examined GWG using gestational age-standardized z-scores, a measure of GWG that by design is uncorrelated with gestational age at measurement and BMI. Z scores of <-1 and >+1 were used to define groups with the smallest and largest normalized weight gains, respectively.

Results: Actigraphy and weight data were available for 751 women. The majority of women (74.8%) had a SD between 7 to <9 hours; 2.1% and 5.2% had a SD of <6 and >9 hours/night, respectively. Non-linear relationships were observed between SD and GWG (see Table). For all GWG assessments, large GWG (Z>+1) became less frequent as SD increased. Women with the shortest (<6) and the longest (> 9) SD had the highest rates of small GWG ( Z<-1). Differences were statistically significant for GWG at Visit 2 and Visit 3 (p<.0001, p=.04) and were similar in magnitude for the last weight prior to delivery (p=0.0504).

Conclusion: Our data suggests that both short and long SD in pregnancy are associated with GWG. Poor sleep in pregnancy has been linked to adverse pregnancy outcomes, and our findings provide one potential mechanism for this association.

Abstract 33

Study Shows Increased Risk of Early Mortality in Women with Hypertensive Disease During Pregnancy

ATLANTA (Feb. 1, 2016)—In a study to be presented on Feb. 5 at 8 a.m. EST, at the Society for Maternal-Fetal Medicine’s annual meeting, The Pregnancy Meeting™, in Atlanta, researchers will present findings from a study titled, Long-term mortality risk following hypertensive disease of pregnancy (HDP).

It has long been recognized that pregnancy puts considerable stress on the body and that there are specific conditions during pregnancy that will indicate lifelong health issues. The objective of this study was to assess whether women with a history of any hypertensive disease during pregnancy have increased risk for early mortality and to determine the timing and most common cause of their deaths.

The study looked at births from 1939 to 2012 using the Utah Population Database. Based on birth certificate data, researchers assigned a diagnosis of HDP and, when possible, the category of disease (gestational hypertension, preeclampsia, HELLP syndrome—a serious complication of high blood pressure during pregnancy, and eclampsia).  Exposed women had a singleton pregnancy complicated by HDP and lived in Utah for more than a year following delivery. Primary cause of death was ascertained from death certificates.

Of 2,083,331 birth certificates evaluated, 61,727 (3%) had HDP.  Of these, all-cause mortality was significantly increased for women with a history of HDP. They also had the greatest risk of mortality due to Alzheimer’s disease, diabetes, ischemic heart disease, and stroke.

“We now know that women with a history of any category of HDP are at increased risk for mortality from a variety of causes,” stated Lauren Theilen, M.D. one of the researchers on the study who will present the findings at the SMFM annual meeting. Dr. Theilen is with the University of Utah Health Sciences Center in Salt Lake City.  “It’s important for physicians who care for these women beyond their childbearing years to recognize the significance of a history of HDP so that these women may receive appropriate screening and intervention,” Theilen added.

The study concluded that women with a history of HDP have increased risk of early mortality with the highest hazard ratios for neurologic, endocrine and circulatory causes.  Increased mortality risk for these women begins approximately 20 years after pregnancy.

# # #

A copy of the abstract is available at http://www.smfmnewsroom.org and below.  For interviews please contact Vicki Bendure at Vicki@bendurepr.com 202-374-9259 (cell).

The Society for Maternal-Fetal Medicine (est. 1977) is the premiere membership organization for obstetricians/gynecologists who have additional formal education and training in maternal-fetal medicine.  The society is devoted to reducing high-risk pregnancy complications by sharing expertise through continuing education to its 2,000 members on the latest pregnancy assessment and treatment methods. It also serves as an advocate for improving public policy, and expanding research funding and opportunities for maternal-fetal medicine. The group hosts an annual meeting in which groundbreaking new ideas and research in the area of maternal-fetal medicine are shared and discussed.  For more information visit www.smfm.org.

Abstract 45    Long-term mortality risk following hypertensive disease of pregnancy (HDP)

Authors: Lauren Theilen1,2, Alison Fraser3, Michael Hollingshaus4, Karen Schliep1, Michael Varner1,2, Ken Smith3, Sean Esplin1,2

1University of Utah Health Sciences Center, Salt Lake City, UT, 2Intermountain Healthcare, Salt Lake City, UT, 3Huntsman Cancer Institute, Salt Lake City, UT, 4University of Utah, Salt Lake City, UT

Objective: To assess whether women with a history of HDP have increased risk for early mortality, and to determine the timing and most common causes of their deaths.

Study Design: We defined a cohort of births from 1939-2012 using the Utah Population Database. Based on birth certificate data, we assigned a diagnosis of HDP and, when possible, the category of disease [gestational hypertension (GHTN), preeclampsia (PRE), HELLP syndrome, and eclampsia (ECL)]. Exposed women had a singleton pregnancy complicated by HDP and lived in Utah for ≥1 year after delivery. Women with >1 pregnancy with HDP were included only once, in the most severe group. Exposed women were matched (1:2) to women without HDP by age, year of childbirth, and parity at time of index pregnancy. Primary cause of death was ascertained from death certificates. Mortality risk by primary cause of death was compared between exposed women (stratified by category of disease) and unexposed women using Cox regression to adjust for infant sex, parental education, ethnicity, and marital status.

Results: Of 2,083,331 birth certificates evaluated, 61,727 (3.0%) unique women had HDP (GHTN 49,438, PRE 29,941, HELLP 921, ECL 1,137) in >1 pregnancy. These women were matched to 123,454 unexposed women. A total of 11,278 women had known death dates: 4,516 (7.3%) exposed and 6,762 (5.5%) unexposed. All-cause mortality was significantly increased among exposed women (HR 1.68, p<0.01) (Table 1). Exposed women had the greatest risk of mortality due to Alzheimer’s disease (HR 3.44, p<0.01), diabetes (HR 3.22, p<0.01), ischemic heart disease (HR 2.28, p<0.01), and stroke (HR 1.92, p<0.01). Hazard ratios for causes of mortality varied by category of HDP. Figure 1 illustrates the survival curve in years after the index pregnancy for women with each category of HDP.

Conclusion: Women with a history of HDP have increased risk of early mortality, with highest hazard ratios for neurologic, endocrine, and circulatory causes. Increased mortality risk begins 20 years after the exposed pregnancy.

Abstract 45-1 Abstract 45-2